Improved Treatments on the Horizon for Elderly CLL Patients

Published on

Topics include: Treatment

Elderly patients are not being forgotten when it comes to the many developments and improved treatments for chronic lymphocyctic leukemia (CLL).  Most people are diagnosed with CLL in their senior years.  However, in the past, some of the most powerful therapies were thought to be too strong for elderly patients.  But now, the newest and most effective therapies are becoming available to patients of all ages.  Dr. Barbara Eichhorst, a CLL expert from Cologne, Germany, explains more in this interview with Andrew Schorr.


Watch now as Dr. Eichhorst discusses how elderly patients can benefit from new CLL treatments coming down the pike.

View more programs featuring

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Hello and welcome to Patient Power.  I'm Andrew Schorr. 

There are a lot of new medicines in development for CLL, and, fortunately, elderly patients are not being excluded when we consider who can benefit.  That was discussed at the 9th European Congress on Hematologic Malignancies, and the speaker was Dr. Barbara Eichhorst from Cologne, Germany.  She joins us now to give us the latest. 

Dr. Eichhorst:

Yes, I think, the first data shows new drugs, which work more specific on CLL cells,  have a very good toxicity profile.  They seem to be an ideal drugs, especially for the treatment of the elderly and comorbid patients, and therefore I expect that the treatment will change in these patients in the future. 

Andrew Schorr:

So, Dr. Eichhorst, you are optimistic for patients today. 

Dr. Eichhorst:

Yes, I'm very optimistic, but there are still some subgroups of patients where we definitely will need much improvement, as it is with those patients with the 17p deletion, for example, and also, patients with a transformation, though, there are some groups which already do very well with chemotherapy regimen, and there are some groups, in whom, we need more urgent, better and new treatments. 

Andrew Schorr:

With all the new medicines being studied, Dr. Eichhorst, do you feel patients of any age, if they have more aggressive CLL, should consider enrolling in a clinical trial? 

Dr. Eichhorst:

Definitely.  Definitely I would recommend, always, to participate in a clinical trial. 

Andrew Schorr:

Dr. Barbara Eichhorst from Cologne, Germany, thank you so much for being with us today. 

Dr. Eichhorst:

Thank you very much.  It was a pleasure. 

Andrew Schorr:

Good news for CLL patients, age is not a limiting factor when it comes to receiving the most modern medicines. 

Thank you for joining us.  I'm Andrew Schorr.  Remember, knowledge can be the best medicine of all. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on December 13, 2013